AbbVie (ABBV)Officer sold ~$641K

~$641K

Approx. value · 3,234.17 sh @ $198.27

68K

Holds after · shares reported

Traded

Aug 5, 2025

Filed

Aug 7, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Sep 26, 2024CongressDisclosed purchase of ABBV — reported range $1,001 - $15,000
2. May 15, 2025CongressDisclosed purchase of ABBV — reported range $1,001 - $15,000
3. May 22, 2025CongressDisclosed purchase of ABBV — reported range $1,001 - $15,000
4. Jun 10, 2025FDAFDA drug approval: Mavyret
5. Jun 10, 2025FDAFDA drug approval: Mavyret
6. Jun 17, 2025CongressDisclosed purchase of ABBV — reported range $1,001 - $15,000
7. Jul 11, 2025CongressDisclosed sale of ABBV — reported range $1,001 - $15,000
8. Jul 22, 2025Congress · 1 personMembers of Congress: 1 purchase, 1 sale
9. Aug 4, 2025CongressDisclosed purchase of ABBV — reported range $1,001 - $15,000
10. Aug 5, 2025 · this disclosureInsiderOfficer sold ~$641K of ABBV shares in the open market

What came next

1. Aug 5, 2025InsiderOfficer sold ~$2M of ABBV shares in the open market
2. Aug 11, 2025CongressDisclosed partial sale of ABBV — reported range $1,001 - $15,000
3. Aug 12, 2025InsiderOfficer sold ~$8.41M of ABBV shares in the open market
4. Aug 14, 2025CongressDisclosed partial sale of ABBV — reported range $1,001 - $15,000
5. Aug 22, 2025CongressDisclosed partial sale of ABBV — reported range $1,001 - $15,000
6. Sep 3, 2025FDAFDA drug approval: Skyrizi
7. Sep 3, 2025FDAFDA drug approval: Skyrizi
8. Oct 3, 2025Company filing · Form 8-K · ResultsReported its results
9. Oct 10, 2025FDAFDA drug approval: Rinvoq
10. Oct 30, 2025Federal contract · $21K obligatedDepartment of Defense awarded AbbVie: $21K obligated to date
11. Oct 30, 2025Congress · 1 personMembers of Congress: 1 purchase, 1 sale
12. Oct 31, 2025Company filing · Form 8-K · ResultsReported its results
13. Oct 31, 2025CongressDisclosed sale of ABBV — reported range $1,001 - $15,000
14. Nov 4, 2025FDAFDA drug approval: Linzess
15. Nov 10, 2025Layoff notice · 5996 Gleason Drive Dublin CA 94568Layoff notice filed in CA: 48 employees
16. Nov 10, 2025Layoff notice · 7041 Las Positas Road Livermore CA 94551Layoff notice filed in CA: 9 employees
17. Nov 10, 2025Layoff notice · 4410 Rosewood Drive Pleasonton CA 94588Layoff notice filed in CA: 2 employees

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for AbbVie

For AbbVie, OQRO holds 2 insider filings (SEC Form 4 or Form 144), 2 Congress trade reports, 130 fund holdings reports (13F) and 2 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ABBV page.

Other recent filings by Nicholas Donoghoe, EVP, CHIEF BUS/STRAT OFFICER

• SEC Form 4 at AbbVie (ABBV)Aug 18, 2026
• SEC Form 4 at AbbVie (ABBV)Aug 7, 2025

The full history of Nicholas Donoghoe, EVP, CHIEF BUS/STRAT OFFICER is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at AbbVie

• House Clerk periodic transaction reportSep 18, 2026
• SEC Form 13F-HRAug 26, 2026
• SEC Form 13F-HRAug 25, 2026
• SEC Form 4Aug 18, 2026
• SEC Form 13F-HRAug 17, 2026
• SEC Form 144Aug 14, 2026

Everything OQRO holds on this company is on its ABBV page.